Nitrosamines

US FDA Guidance on Control and Acceptable Intake of Nitrosamine Impurities in Human Drugs

FDA has consolidated its framework for managing nitrosamine impurities in human drugs through final guidances on manufacturing controls and acceptable intake limits, now highlighted in a dedicated overview for patients, prescribers, and manufacturers. Drug makers should treat nitrosamine risk assessment, analytical testing, and adherence to FDA acceptable-intake thresholds as ongoing compliance obligations across all prescription and OTC products, with reformulation and recalls where levels cannot be controlled.

21 Apr 2026, 17:26fda.govUnited States

Hawaii HCR 84 Seeks DOE Plan To Phase Out Processed Meats In School Meals By 2032

Hawaii lawmakers are advancing HCR 84, a concurrent resolution asking the state Department of Education to develop a plan to phase carcinogenic processed meats—linked to nitrite/nitrate-derived nitrosamines—out of school meals by 2032 and to report back before the 2027 legislative session. If adopted, this would push Hawaii’s school meal programmes and their food-service suppliers toward lower-risk, plant-based protein options and could prefigure stricter purchasing standards for processed meat products over the coming years.

16 Apr 2026, 10:22capitol.hawaii.govUnited States

Hawaii Senate Resolution 140 Seeks DOE Plan to Phase Out Processed Meats From School Meals by 2032

In March 2026, Hawaii legislators introduced Senate Resolution 140 asking the Department of Education to develop a plan to phase out processed meats—linked to carcinogenic nitrosamines—from school meals and replace them with healthier protein options by 2032. Although non-binding, this resolution and its adopted House companion signal growing pressure for Hawaii’s school meal programmes and their suppliers to move away from nitrite-preserved processed meats toward plant-based or minimally processed alternatives.

15 Apr 2026, 13:52capitol.hawaii.govUnited States

US FDA Publishes FY 2024 GDUFA Science and Research Report

The US FDA has published its FY 2024 GDUFA report outlining scientific advancements that will define future regulatory standards for generic drugs and complex formulations. Firms should integrate these updated methodologies—particularly regarding nitrosamine impurities and AI-driven bioequivalence—into their development pipelines to mitigate approval risks and accelerate market access.

28 Mar 2026, 18:45fda.govUnited States

US FDA Publishes FY 2025 GDUFA Science and Research Report on Generic Drug Priorities

The US FDA has released its FY 2025 GDUFA Science and Research Report, detailing over 50 projects aimed at accelerating the development and assessment of complex generic drugs. Generic drug sponsors should align their analytical methods and bioequivalence study designs with the FDAs prioritized focus on nitrosamine impurities, complex active ingredients, and the integration of AI and machine learning tools.

27 Mar 2026, 20:22fda.govUnited States

US FDA Publishes FY 2025 Drug Quality Sampling And Testing Results

The US FDA has released its FY 2025 drug quality surveillance results, confirming high compliance across tested pharmaceuticals with only one specific dissolution failure identified. This update signals the agency's continued reliance on risk-based post-market testing to drive enforcement, necessitating rigorous quality control and supply chain oversight for manufacturers.

27 Mar 2026, 20:09fda.govUnited States

EMA Adopts Revised Guideline on the Chemistry of Active Substances for Human Medicines

EMA has finalized revised requirements for the chemistry and manufacture of active substances in human medicines, effective September 2026. Manufacturers must strengthen impurity control strategies and technical justifications for starting materials to ensure compliance with updated safety and quality standards.

26 Mar 2026, 12:25ema.europa.euEuropean Union

US FDA Announces FY 2026 Generic Drug Science and Research Initiatives Public Workshop

The US FDA has scheduled a June 2026 public workshop to define FY 2027 research priorities for generic drugs, focusing on nitrosamine impurities and bioequivalence standards. Stakeholders should engage to influence the technical standards and regulatory pathways that will govern complex generic approvals and product quality requirements.

4 Mar 2026, 16:00federalregister.govUnited States

EU EFSA Peer Review Of Ziram Pesticide Risk Assessment Identifies Critical Concerns

EFSA has identified critical risks in its peer review of the fungicide ziram, including unresolved genotoxicity and significant drinking water contamination. These findings strongly indicate a forthcoming non-renewal of EU approval, necessitating immediate transition planning for manufacturers and agricultural users.

28 Feb 2026, 20:16efsa.onlinelibrary.wiley.comEuropean Union

European Pharmacopoeia Commission Adopts 81 Texts for Ph. Eur. Issue 13.1

The European Pharmacopoeia Commission has adopted 81 new and revised standards for Issue 13.1, effective from January 2027. Manufacturers must update quality control protocols and supply chain specifications to ensure continued compliance and market access for pharmaceutical products and excipients.

22 Dec 2025, 12:20edqm.euEuropean Union

US FDA Determines Zantac Injection Not Withdrawn for Safety, Clearing Path for Generics

The FDA has determined that Zantac injection was not withdrawn for safety reasons, formally clearing a regulatory path for generic market entry. This decision stabilizes the regulatory status of this specific formulation and enables manufacturers to proceed with generic drug applications despite broader historical concerns over nitrosamine impurities.

11 Dec 2025, 20:24federalregister.govUnited States

EU Drafts Standards Mandate on Release of Dangerous Substances from Construction Products

The European Commission has drafted a standardisation mandate for CEN to develop harmonised testing methods for hazardous substances in construction products by 2029. This initiative will enforce mandatory assessment of PFAS, microplastics, and VVOCs, directly impacting product design and market access under the new Construction Products Regulation.

1 Dec 2025, 17:11single-market-economy.ec.europa.euEuropean Union

Parliament Adopts New EU Toy Safety Regulation

The European Parliament has adopted the new Toy Safety Regulation to replace Directive 2009/48/EC and strengthen protections against chemical hazards. Manufacturers must prepare for stricter substance limits and increased ECHA oversight of nitrosamines and heavy metals as the EU modernizes its product safety framework.

25 Nov 2025, 17:28europarl.europa.euEuropean Union

EU Launches Seventh Consultation on New Occupational Exposure Limits for Carcinogens and Reprotoxic Substances

The European Commission has launched a consultation to establish or update Occupational Exposure Limits for seven priority hazardous substances including Chromium VI and nitrosamines. Impacted businesses should evaluate workplace exposure data and socio-economic impacts to influence future compliance thresholds and operational constraints under the CMRD.

10 Nov 2025, 16:19rpaltd.co.ukEuropean Union

Japan Publishes Public Consultation Results on Amendments to Chemical Concentration Standards Under Occupational Safety Rules

Japan has finalized stricter occupational exposure limits for several industrial chemicals under the Industrial Safety and Health Act, with enforcement starting October 2026. Impacted operators must prioritize technical upgrades to exposure controls as regulators align domestic standards with international scientific benchmarks despite industry cost concerns.

10 Oct 2025, 15:38public-comment.e-gov.go.jpJapan

EFSA Reassesses Safety of Nitrates and Nitrites as Food Additives

EFSA has established a new group Acceptable Daily Intake for nitrates and nitrites following a comprehensive safety reassessment of these food additives. While current usage levels remain authorized, the findings increase regulatory pressure on manufacturers to reduce concentrations and enhance monitoring for carcinogenic nitrosamines in processed products.

3 Oct 2025, 07:39science.food.gov.ukEuropean Union

Korea Revises Hygiene Product Laboratory Evaluation for New Product Scope

South Korea is expanding the Hygiene Products Control Act to include oral care products and tattoo dyes starting June 2025. Manufacturers must ensure testing laboratories are prepared for new compliance requirements covering heavy metals, nitrosamines, and phthalates to maintain market access.

25 Sept 2025, 11:56eping.wto.orgSouth Korea

EU Updates REACH Annex XVII With New CMR Restrictions

The European Union has formally updated REACH Annex XVII to restrict the sale of several newly classified CMR substances to the general public starting September 2025. Manufacturers must immediately review consumer-facing product formulations for these substances to ensure compliance with concentration limits or execute necessary phase-outs.

14 Aug 2025, 08:55ec.europa.euEuropean Union

Compliance Checks and Potential Restrictions Proposed for Amine-Terminated Aliphatic Ethers

ECHA has proposed harmonized classification and REACH restrictions for 24 amine-terminated aliphatic ethers following a group-wide regulatory assessment. Companies in the cosmetics, adhesives, and coatings sectors should anticipate mandatory labeling updates and potential market access restrictions for professional and consumer products.

10 Apr 2025, 06:19echa.europa.euEuropean Union

Implementation of New Chinese National Standards on Food Chemicals and Contact Materials

China has enforced 50 new national food safety standards and nine amendments significantly updating specifications for food additives and contact materials. Companies must immediately align testing protocols and supply chain verification with these stricter migration limits and analytical methods to maintain market access.

29 Mar 2025, 10:39gov.cnChina